Technical Analysis for REPL - Replimune Group, Inc.

Grade Last Price % Change Price Change
grade D 11.14 1.27% 0.14
REPL closed up 1.27 percent on Monday, August 19, 2019, on 1.26 times normal volume.
0 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical REPL trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Up 3 Days in a Row Strength 0.00%
Oversold Stochastic Weakness 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.27%
Wide Bands Range Expansion 1.27%
Oversold Stochastic Weakness 1.27%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 7.12%

Older signals for REPL ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Track My Stocks
Configure default chart indicators
Basic chart:
Profile
Replimune Group, Inc. is a clinical-stage biotechnology company. The Company is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The Company applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The Company is focused on developing a pipeline of oncolytic immunotherapy product candidates to provide clinical benefits to cancer patients. Its product candidates include RP, RP2, and RP3. The Company is focused on Phase 1/2 clinical trial with its lead product candidate, RP1, in approximately 150 patients with a range of solid tumors.
Medicine Biotechnology Cancer Clinical Medicine Solid Tumors Immunotherapy Cancer Treatments Virotherapy Experimental Cancer Treatments Transgene Sa
Is REPL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Aug 14 Replimune Group EPS beats by $0.03
Aug 14 Replimune Reports First Fiscal Quarter Financial Results and Provides Corporate Update
Aug 9 Replimune files for $250M mixed shelf
Aug 6 JPMorgan upgrades Insulet after strong Q2
Aug 6 Replimune to Present at 2019 Wedbush PacGrow Healthcare Conference
Jul 19 Imagine Owning Replimune Group (NASDAQ:REPL) And Wondering If The 17% Share Price Slide Is Justified
Jul 8 Canaccord likes Rhythm Pharma in premarket analyst action
Jun 28 Replimune Group EPS beats by $0.58
Jun 28 Replimune Reports Fourth Fiscal Quarter and Year 2019 Financial Results and Provides Corporate Update
Jun 1 Replimune Announces Initiation of the Phase 2 Portion of its Ongoing Phase 1/2 Clinical Trial of RP1 as Monotherapy and in Combination with Nivolumab
See more REPL news...
Indicators
Indicator Value
52 Week High 23.55
52 Week Low 8.88
Average Volume 34,989
200-Day Moving Average 13.4044
50-Day Moving Average 12.673
20-Day Moving Average 11.643
10-Day Moving Average 10.67
Average True Range 0.9729
ADX 17.75
+DI 16.6181
-DI 17.4271
Chandelier Exit (Long, 3 ATRs ) 11.3813
Chandelier Exit (Short, 3 ATRs ) 12.9237
Upper Bollinger Band 13.746
Lower Bollinger Band 9.54
Percent B (%b) 0.38
BandWidth 36.12471
MACD Line -0.68
MACD Signal Line -0.6636
MACD Histogram -0.0164
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.20
Resistance 3 (R3) 13.12 12.35 12.85
Resistance 2 (R2) 12.35 11.83 12.39 12.74
Resistance 1 (R1) 11.75 11.51 12.05 11.83 12.62
Pivot Point 10.98 10.98 11.14 11.02 10.98
Support 1 (S1) 10.38 10.46 10.68 10.46 9.66
Support 2 (S2) 9.61 10.14 9.65 9.54
Support 3 (S3) 9.01 9.61 9.43
Support 4 (S4) 9.09